VITAMIN D
Bone Fracture
Boston VA Research Institute, Inc.mixturePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Bone Fracture cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RISEDRONIC ACID Boston VA Research Institute, Inc. | Phase 4 | BB |
Calcium Boston VA Research Institute, Inc. | Phase 4 | BB |
Sufentanyl West Virginia University | Phase 4 | BB |
TOREMIFENE GTx | Phase 3 | BB |
Zoledronate GlaxoSmithKline | Phase 3 | B |
Denosumab GlaxoSmithKline | Phase 3 | B |
Viosterol Brigham and Women's Hospital | Unknown | D |
Dalteparin M.D. Anderson Cancer Center | N/A | NR |
Same molecule, other indications
VITAMIN D is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →